Diabetes Mellitus
Conditions
Brief summary
Thunder V4 (TV4) is the code name of a blood glucose monitoring system (BGMS) consisting of a new meter and new Contour FIT test strips. This clinical trial will assess the performance (accuracy) of the TV4 meter by lay users enrolled as subjects in the study, and by health care professionals (also called study staff).
Detailed description
The study will be conducted at three clinical sites and enroll a total of approximately 402 lay users. Ten to fifteen percent (10 - 15%) of the enrolled subjects will be naïve users (naïve to SMBG's and may include people without diabetes). At least twenty percent (20%) of subjects enrolled with diabetes will have Type 1 diabetes. At least 70% of subjects will be younger than age 65. Sites will also enroll subjects of Chinese descent. This clinical investigation will be conducted within the US.
Interventions
DEVICECapillary Testing
Testing Contour Fit BGMS with capillary blood
DEVICEAlternative Site Testing (AST)
Testing Contour Fit BGMS using blood from alternative site
DEVICEVenous Testing
Testing Contour Fit BGMS with venous blood
Sponsors
Ascensia Diabetes Care
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Males and females, 18 years of age and older * Ability to speak, read and understand English. Subjects must demonstrate the ability to read a paragraph from the first page of the User Guide (UG) to qualify for the study. * Willing to complete all study procedures
Exclusion criteria
* Subjects without diabetes that are not naïve to Blood Glucose Monitoring System. * Hemophilia or any other bleeding disorder * Pregnancy (self-reported) * Physical, visual or neurological impairments that would make the person unable to perform testing with the BGMS. * Previous use of the Ascensia Contour Thunder V3 (TV3), or Thunder PLUS (T-PLUS), or Thunder V4 (TV4) BGMS. * Working for a medical laboratory, hospital or another clinical setting that involves training on, or clinical use of blood glucose monitors. * Being in this trial during or soon after xylose absorption testing (Xylose in the blood is known to cause interference). However, subjects can be enrolled as soon as 2 days after the test is performed (25 gms of oral xylose administered during this test is cleared within 480 mins or 8 hours). * A condition, which in the opinion of the investigator or designee, would put the person or study conduct at risk. The reason for exclusion will be clearly documented by investigator or designee on the subject disposition form. * Working for a competitive medical device company, or having an immediate family member or someone who is not a family member but is living within the household of someone who works for such a company. * Immediate family members are the subject's parents, spouse, children, and siblings, including the parent's spouse; step-children and adopted children and their spouses. * A competitive medical device company is a company that provides a medical device or components of a device that is related to diabetes. For example, people who are not eligible are those who work for companies that create or manufacture the following (or a company that is in a partnership with a company that provides such devices): lancing devices, blood glucose monitoring systems, continuous glucose monitoring systems, insulin pens, or systems related to the measurement of HbA1c. People who are eligible are those who work for companies associated with products such as wound dressings, medications or dietary products.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fingerstick Test: Obtain TV4 BGMS performance data in the hands of lay users with diabetes using fingerstick capillary blood obtained with Microlet NEXT® lancing device. | 4 weeks | Number of glucose results falling within ±15mg/dL of laboratory method at glucose concentration \<100 mg/dL and within ±15% at glucose concentrations ≥100 mg/dL |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Alternative Site Test (AST): Obtain TV4 BGMS performance data in the hands of lay users with diabetes using capillary blood from the palm site obtained with Microlet NEXT lancing device with the AST endcap. | 4 weeks | Number of glucose results falling within ±15mg/dL of laboratory method at glucose concentration \<100 mg/dL and within ±15% at glucose concentrations ≥100 mg/dL |
| Venous Blood Test: Obtain TV4 BGMS performance data using venous blood from lay users with diabetes. | 4 weeks | Number of glucose results falling within ±15mg/dL of laboratory method at glucose concentration \<100 mg/dL and within ±15% at glucose concentrations ≥100 mg/dL |
| Subject Questionnaire on the Usability of TV4 BGMS | 4 weeks | Number of results with scores of 3 or higher to statements concerning instructions for use or ease of use. Scores of 3 or greater (on a scale of 0 to 5) are more favorable to usability. |
Countries
United States
Outcome results
None listed